These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Comparison of the bactericidal activity of trovafloxacin and ciprofloxacin, alone and in combination with cefepime, against Pseudomonas aeruginosa. McNabb J; Quintiliani R; Nightingale CH; Nicolau DP Chemotherapy; 2000; 46(6):383-9. PubMed ID: 11053903 [TBL] [Abstract][Full Text] [Related]
8. Prediction of the effects of inoculum size on the antimicrobial action of trovafloxacin and ciprofloxacin against Staphylococcus aureus and Escherichia coli in an in vitro dynamic model. Firsov AA; Vostrov SN; Kononenko OV; Zinner SH; Portnoy YA Antimicrob Agents Chemother; 1999 Mar; 43(3):498-502. PubMed ID: 10049257 [TBL] [Abstract][Full Text] [Related]
9. Activity of the new fluoroquinolone trovafloxacin (CP-99,219) against DNA gyrase and topoisomerase IV mutants of Streptococcus pneumoniae selected in vitro. Gootz TD; Zaniewski R; Haskell S; Schmieder B; Tankovic J; Girard D; Courvalin P; Polzer RJ Antimicrob Agents Chemother; 1996 Dec; 40(12):2691-7. PubMed ID: 9124824 [TBL] [Abstract][Full Text] [Related]
10. Activities of trovafloxacin compared with those of other fluoroquinolones against purified topoisomerases and gyrA and grlA mutants of Staphylococcus aureus. Gootz TD; Zaniewski RP; Haskell SL; Kaczmarek FS; Maurice AE Antimicrob Agents Chemother; 1999 Aug; 43(8):1845-55. PubMed ID: 10428901 [TBL] [Abstract][Full Text] [Related]
11. Prediction of the antimicrobial effects of trovafloxacin and ciprofloxacin on staphylococci using an in-vitro dynamic model. Firsov AA; Vasilov RG; Vostrov SN; Kononenko OV; Lubenko IY; Zinner SH J Antimicrob Chemother; 1999 Apr; 43(4):483-90. PubMed ID: 10350376 [TBL] [Abstract][Full Text] [Related]
13. Pharmacodynamics of trovafloxacin in a mouse model of cephalosporin-resistant Streptococcus pneumoniae pneumonia. Ng W; Lutsar I; Wubbel L; Ghaffar F; Jafri H; McCracken GH; Friedland IR J Antimicrob Chemother; 1999 Jun; 43(6):811-6. PubMed ID: 10404320 [TBL] [Abstract][Full Text] [Related]
14. Efficacy of trovafloxacin in treatment of experimental staphylococcal or streptococcal endocarditis. Entenza JM; Vouillamoz J; Glauser MP; Moreillon P Antimicrob Agents Chemother; 1999 Jan; 43(1):77-84. PubMed ID: 9869569 [TBL] [Abstract][Full Text] [Related]
15. A new approach to in vitro comparisons of antibiotics in dynamic models: equivalent area under the curve/MIC breakpoints and equiefficient doses of trovafloxacin and ciprofloxacin against bacteria of similar susceptibilities. Firsov AA; Vostrov SN; Shevchenko AA; Portnoy YA; Zinner SH Antimicrob Agents Chemother; 1998 Nov; 42(11):2841-7. PubMed ID: 9797213 [TBL] [Abstract][Full Text] [Related]
16. Inter- and intraquinolone predictors of antimicrobial effect in an in vitro dynamic model: new insight into a widely used concept. Firsov AA; Shevchenko AA; Vostrov SN; Zinner SH Antimicrob Agents Chemother; 1998 Mar; 42(3):659-65. PubMed ID: 9517948 [TBL] [Abstract][Full Text] [Related]
18. Should Pseudomonas aeruginosa isolates resistant to one of the fluorinated quinolones be tested for the others? Studies with an experimental model of pneumonia. Chidiac C; Roussel-Delvallez M; Guery B; Beaucaire G Antimicrob Agents Chemother; 1995 Mar; 39(3):677-9. PubMed ID: 7793872 [TBL] [Abstract][Full Text] [Related]